Barclays PLC Has $20.67 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

Barclays PLC lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 50.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 393,418 shares of the company’s stock after selling 407,984 shares during the quarter. Barclays PLC owned 0.72% of LivaNova worth $20,671,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Arizona State Retirement System grew its position in LivaNova by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after purchasing an additional 299 shares in the last quarter. Atria Investments Inc grew its holdings in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after buying an additional 331 shares in the last quarter. Fifth Third Bancorp raised its position in LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the period. State of Alaska Department of Revenue raised its position in LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock valued at $328,000 after buying an additional 425 shares during the period. Finally, Rhumbline Advisers lifted its stake in LivaNova by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock worth $10,039,000 after acquiring an additional 659 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Monday, November 25th. Finally, Robert W. Baird increased their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

Shares of LivaNova stock opened at $51.50 on Friday. LivaNova PLC has a 1-year low of $43.15 and a 1-year high of $64.47. The firm has a fifty day simple moving average of $51.97 and a 200-day simple moving average of $51.49. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of 122.62 and a beta of 0.98.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.